Skip to content
Specialized Packaging Market Intelligence and Strategic AdvisoryPackaging Intelligence. Clearer Decisions. Stronger Growth.
SPI Buyers Database

Pharma and health

GSK packaging profile

GSK is a biopharma company making medicines and vaccines. It uses recycled card in packaging and e-leaflets for vaccines.

By the SPI teamSources consulted 13 October 2026Status: LiveSourced from company reports; not yet re-checked by a second SPI team member.How this database works
Company profile

At a glance

Legal name
GSK plc1
Incorporated
England1
Headquarters
79 New Oxford Street, London, WC1A 1DG, England1
Listing
London Stock Exchange: GSK; New York Stock Exchange (American Depositary Shares): GSK1
Financial year end
31 December1
Turnover
GBP 32,667 million (2025); GBP 31,376 million (2024)2
Employees
66,8001
Markets
Local offices in about 60 countries and territories plus about 50 more served under a third-party distribution model (company contact page)5
Website
gsk.com4
End uses
Pharma and health
The business

Business and brands

Sales by category

  • Specialty Medicines41%2
  • Vaccines28%2
  • General Medicines31%2

SPI calculation from reported turnover, rounded, 2025.

Brands by category

Specialty Medicines: HIV2
  • Dovato
  • Cabenuva
  • Apretude
Specialty Medicines: Respiratory, Immunology and Inflammation2
  • Nucala
  • Benlysta
Specialty Medicines: Oncology2
  • Jemperli
  • Zejula
  • Ojjaara/Omjjara
  • Blenrep
Vaccines2
  • Shingrix
  • Bexsero
  • Penmenvy
  • Arexvy
General Medicines: Respiratory2
  • Trelegy
General Medicines: Respiratory (salbutamol metered dose inhaler)6
  • Ventolin
Markets

Geographic footprint

  • US turnover GBP 16,859m, Europe GBP 7,533m and International GBP 8,275m in 2025, so the US is just over half of turnover (SPI calculation).2
  • United States (GBP 16,859m in 2025)2
  • 66,800 people across 70 countries1
As the company reports it

Packaging profile

Formats and materials the company itself reports using, in its own reporting. No pack specifications, volumes or supplier names beyond what it has published.

FormatMaterialWhat the company reports
CartonPaper/board, recycledRecycled card used in packaging4
Patient information leafletPaper (avoided)E-leaflets for vaccines (replacing paper leaflets)4
Aluminium packaging (format not specified)AluminiumAluminium packaging supply chain targeted under the Sustainable Procurement Programme; engagement with it drove a 3% cut in supply chain waste3
Paper packagingPaper/boardPaper packaging is one of 12 key naturally-derived materials for sustainable sourcing; 51% of those materials were sustainably sourced and deforestation free in 2025 (all 12 combined, not paper alone)3
Metered dose inhalerPropellant (HFA-134a to HFA-152a)Ventolin salbutamol metered dose inhaler accounts for 43% of GSK's total carbon footprint; a version with the low carbon propellant HFA-152a (replacing HFA-134a) could cut emissions per inhaler by about 92%3

Reporting scope: GSK does not publish a plastic packaging footprint or plastic-specific targets in the sources reviewed. Packaging is covered by a combined product and packaging environmental impact target measured as carbon reductions from eco-design.3

Packaging suppliers

No packaging supplier relationship is publicly announced in the sources reviewed. The report names supplier engagement on aluminium packaging without naming suppliers.

Industry and recycling partners named by the company3

  • Sustainable Markets Initiative Health Systems Task Force (co-led by GSK)
  • Pharmaceutical Supply Chain Initiative (audit guidelines)
The register

Packaging targets and progress

Targets and progress are taken from each company's own published reports, with a quote and a link on its page. Status shows met or missed only where the company has reported the result. No contacts, purchase volumes, supplier relationships or pack specifications are listed.

Other In progress By 2030 Sourced, not yet re-checked

25% environmental impact reduction for product and packaging by 2030

Latest reported: Scope and methodology finalised in 2025; 42% of in-scope products have environmental impact reduction plans (plans for all by end 2026)

From the source“25% environmental impact reduction for our products and packaging by 2030”

GSK – Responsible Business 2025 (Annual Report 2025)

Other In progress By 2030 Sourced, not yet re-checked

10% reduction in supply chain waste from a 3.8 million tonne 2022 upstream baseline by 2030

Latest reported: 3% reduction (2025), mainly through engagement with the aluminium packaging supply chain

From the source“10% waste reduction from our supply chain by 2030”

GSK – Responsible Business 2025 (Annual Report 2025)

Commitments

Commitments and baselines

Every packaging and supply-chain commitment the company has published, with its baseline and the latest progress it reports. Status says met or missed only where the company states the result.

CommitmentByBaselineLatest reportedStatus
GSK environment targets25% environmental impact reduction for products and packaging by 2030 (measured as carbon reductions from eco-design)32030–Scope and methodology finalised in 2025; 42% of in-scope products have environmental impact reduction plans; plans for all in-scope products targeted by end 2026In progress
GSK environment targets10% reduction in supply chain waste from the upstream baseline of 3.8 million tonnes (2022)320303.8 million tonnes (2022)3% reduction, mainly from engagement with the aluminium packaging supply chain (2025)In progress
GSK environment targetsSustainable sourcing of 12 key naturally-derived materials, including paper packaging (deforestation free)32030–51% of the 12 materials sustainably sourced and deforestation free (not split out for paper) (2025)In progress
GSK environment targetsScope 3 reduction against 2020 baseline (supply chain emissions include purchased packaging)3Purchased goods include packaging, so suppliers are inside this target (SPI note). Target level and year not captured in the section read.2020Scope 3 emissions 16% below 2020 baseline; supply chain emissions down 6% in 2025In progress

Initiatives and pacts the company names

  • No Ellen MacArthur Global Commitment or Plastics Pact membership found in the sources reviewed3 as of 2026
  • Sustainable Markets Initiative Health Systems Task Force (co-lead)3 as of 2025
SPI analysis

What the commitments mean

GSK has no plastic packaging target. Packaging enters its environment targets in three places. The first is a 25% environmental impact reduction for products and packaging by 2030, measured as carbon reductions from eco-design, whose scope and methodology were finalised in 20253. Sustainable Design Plans, covering design through disposal, apply to all medicines newly developed or acquired from 20244. The second is a 10% cut by 2030 in supply chain waste, set against an upstream baseline of 3.8 million tonnes in 20223. The third is sustainable, deforestation-free sourcing of 12 key naturally-derived materials, one of which is paper packaging3.

These targets frame packaging as a carbon and waste question rather than a recyclability one, which fits the product mix: on SPI's rounding of reported turnover, specialty medicines were about 41% of 2025 sales, vaccines 28% and general medicines 31%2. The carton and leaflet changes it reports are recycled card in packaging and e-leaflets for vaccines4, and the supply chain waste work has so far run mainly through the aluminium packaging supply chain3.

The largest product lever is a propellant rather than a packaging material: the Responsible Business 2025 report puts the Ventolin metered dose inhaler at 43% of GSK's carbon footprint3, and an EU application for a version using HFA-152a was filed on 4 September 20267. GSK also takes part in industry take-back schemes for medical devices in Denmark, Singapore and Switzerland4. No Ellen MacArthur or Plastics Pact membership was found.

SPI analysis

Progress against targets

SPI analysis Our reading of the sourced facts above. Not company-reported, not legal advice.

Product and packaging impact: no percentage reduction has been reported yet. In 2025, 42% of in-scope products had environmental impact reduction plans, with plans for all in-scope products due by the end of 20263. SPI calculation: 58 points of plan coverage must be added in about one year before any carbon saving can be counted toward the 25% by 2030.

Supply chain waste: a 3% reduction against the 3.8 million tonne 2022 baseline by 20253. SPI calculation: 3% of 3.8 million tonnes is about 114,000 tonnes, and the 10% goal is about 380,000 tonnes, leaving about 266,000 tonnes, or 7 points, over five years. That is 1.4 points a year against the 1.0 point a year achieved between 2022 and 2025.

Deforestation-free materials: 51% of the 12 materials were sustainably sourced and deforestation free in 20253. Paper packaging is not split out, so its own progress is unknown.

Scope 3: emissions were 16% below 2020, with supply chain emissions down 6% in 20253. The target level and year were not captured, so the pace cannot be tested.

Ventolin: the phase III release of 22 October 2025 gave a possible cut of about 92% in emissions per inhaler and described Ventolin as 45% of the footprint6, against 43% in the annual report. SPI does not reconcile the two figures. Either way, with first launches expected in 2027 if approved7, the propellant switch is likely to outweigh any packaging-material saving in GSK's carbon totals.

Last 24 months

Recent packaging developments

  1. GSK filed a regulatory application in the EU for a lower carbon Ventolin metered dose inhaler using the HFA-152a propellant; first launches expected in 2027 if approved.7

  2. Positive pivotal phase III data for a low carbon version of the Ventolin inhaler (HFA-152a), with potential to cut greenhouse gas emissions per inhaler by 92%; Ventolin is close to half (45%) of GSK's global carbon footprint.6

SPI analysis

Regulatory exposure

SPI analysis Our reading of the sourced facts above. Not company-reported, not legal advice.

Basis: Presence is taken from GSK's worldwide contact page5, which separates countries with local offices from countries served under a third-party distribution model, and from regional turnover2. Rule IDs are from the SPI Regulation Tracker. GSK sells prescription medicines and vaccines, so food-contact, beverage deposit and single-use foodware rules are not applied. Several packaging laws treat medicinal packaging differently; those carve-outs were not checked. Not legal advice.

JurisdictionRules in the Regulation Tracker
European UnionLocal offices with addresses in Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Poland, Portugal, Spain, Sweden and other EU state

Cartons, leaflets, blisters and inhaler packs fall under the PPWR framework. The PPWR treats medicinal product packaging differently in places (for example contact-sensitive packaging and recycled content); the carve-outs were not checked in this session, so recycled-content and recyclability rules are listed as possible exposure only.

GermanyLocal office listed5
FranceLocal office listed5

Triman and Info-tri labelling; medicines packaging treatment not checked.

SpainLocal office listed5

Spanish plastic packaging tax applies to non-reusable plastic packaging; any medicines exemption was not checked.

AustriaLocal office listed5

Tracker rule is beverage deposit only; not relevant to the product mix.

IrelandLocal office listed5

Tracker rule is beverage DRS only.

PortugalLocal office listed5

Tracker rule is beverage DRS only.

PolandLocal office listed5

Tracker rule is beverage DRS only.

United KingdomHeadquarters, London1

UK Plastic Packaging Tax and packaging EPR. A UK PPT relief for immediate packaging of licensed human medicines may apply; not verified in this session.

United StatesLocal office listed5; US turnover GBP 16,859m in 2025, the largest region2

State packaging EPR laws define exemptions for some drug and medical packaging that differ by state; applicability to GSK products not checked.

CanadaLocal office listed5
IndiaLocal office listed5

Plastic packaging EPR registration as a brand owner. Recycled-content and reuse rules (PR-IN-002, PR-IN-003) may carry pharma-specific treatment; not checked. GSK Pharmaceuticals Limited in India is a separately listed company (not profiled here).

ChinaLocal office listed (China Mainland)5

GB 23350-2021 covers food and cosmetics, not medicines; no direct match.

JapanLocal office listed5
AustraliaLocal office listed5

Proposed national EPR scheme.

New ZealandLocal office listed5

Tracker rules are single-use plastic item phase-outs; no direct match.

VietnamLocal office listed5
PhilippinesLocal office listed5
IndonesiaLocal office listed5
ChileLocal office listed5
ColombiaLocal office listed5
BrazilLocal office listed5
KenyaListed under a third-party distribution model5

Whether GSK or its distributor is the obligated producer was not checked.

South AfricaListed under a third-party distribution model5

Whether GSK or its distributor is the obligated producer was not checked.

United Arab EmiratesLocal office listed5

Dubai rule targets single-use products; no direct match.

Plastic taxes: Plastic taxes in the tracker that could touch the mix: UK Plastic Packaging Tax (PR-GB-001) and Spain's non-reusable plastic packaging tax (PR-ES-001), both subject to any medicines reliefs, which were not checked. The EU plastic own resource (PR-EU-017) is paid by Member States.

SPI analysis

Exposure by market

United Kingdom

GSK is headquartered in London1. PR-GB-002 and PR-GB-003 apply to cartons, leaflets and inhaler secondary packs placed on the UK market, with fees modulated by recyclability from 2026-27. Plastic Packaging Tax under PR-GB-001, now GBP 228.82 per tonne, falls on components below 30% recycled plastic; a relief for immediate packaging of licensed human medicines may apply but was not checked.

United States

The US was GSK's largest region, with GBP 16,859 million of 2025 turnover2. Packaging for products such as Shingrix, Arexvy and Trelegy sold in Oregon, Colorado and California falls under PR-US-002, PR-US-003 and PR-US-004 unless a state drug packaging exemption applies; those exemptions differ by state and were not checked.

European Union

Europe turnover was GBP 7,533 million in 20252, with local offices in Germany, France, Spain, Italy and other Member States5. The PPWR (PR-EU-001) reaches cartons, leaflets and transport packaging, where vaccine e-leaflets4 already cut paper. How PR-EU-010's 2030 recyclability test treats medicinal packaging was not checked.

Spain

GSK has a Spanish local office5. Blister and inhaler packaging could fall under the EUR 0.45/kg tax on non-recycled plastic in PR-ES-001 unless a medicines exemption applies, while PR-ES-002 brings shippers and other commercial packaging into EPR.

India

GSK lists an Indian local office5; GSK Pharmaceuticals Limited is a separately listed Indian company not covered here. PR-IN-001 requires brand owners of plastic-packaged goods to register on the CPCB portal and meet category-wise EPR targets, which reaches bottle and blister packs. How PR-IN-002 treats pharmaceutical packaging was not checked.

SPI analysis

What this means for packaging suppliers

SPI analysis Our reading of the sourced facts above. Not company-reported, not legal advice.

GSK does not set plastic packaging targets; its packaging agenda runs through carbon. The 25% product and packaging impact target is measured as carbon cut through eco-design, with reduction plans for all in-scope products due by end 2026, so 2026 to 2027 is when packaging redesign briefs are likely to land. The supply chain waste target is already being worked through aluminium packaging suppliers, which signals demand for lower-waste aluminium (for example blister foil and tubes, though GSK does not name formats). The switch of Ventolin to the HFA-152a propellant, with EU launches expected from 2027, will touch inhaler components, canisters and secondary packs. Recycled card and e-leaflets show a steady move to lighter, fibre-based secondary packaging, and paper is inside GSK's deforestation-free sourcing work, so certified-fibre suppliers are better placed. No supplier relationship has been publicly announced; this describes likely demand, not who supplies.

Questions

Questions

Does GSK have a plastic packaging target?

No plastic-specific packaging target appears in GSK's Responsible Business 2025 report or on its materials and waste page, as of 14 October 202634. Packaging is covered by a 25% product and packaging environmental impact reduction target for 2030, measured as carbon.

How is GSK cutting supply chain waste?

GSK targets a 10% reduction in supply chain waste by 2030 from a 2022 upstream baseline of 3.8 million tonnes3. It reported a 3% reduction in 2025, mainly from engagement with the aluminium packaging supply chain.

What is GSK changing in vaccine and medicine packaging?

GSK uses e-leaflets for vaccines in place of paper leaflets and recycled card in packaging4. Since 2024 all newly developed or acquired medicines have Sustainable Design Plans covering design through disposal.

What is the low carbon Ventolin inhaler?

It is a version of the Ventolin salbutamol metered dose inhaler using the HFA-152a propellant instead of HFA-134a, with potential to cut greenhouse gas emissions per inhaler by about 92%6. GSK filed for EU approval on 4 September 2026 and expects first launches in 2027 if approved7.

Does GSK take back used devices?

GSK says it takes part in industry take-back schemes for medical devices in Denmark, Singapore and Switzerland and is exploring similar schemes elsewhere4. No collection tonnage had been published as of October 2026.

Limits

Data gaps

What the sources reviewed do not show, or what we could not confirm. Know something we have missed? Tell the SPI team and we will check it.

  • No packaging supplier relationships are publicly announced in the sources reviewed.
  • GSK publishes no plastic packaging tonnage, recycled-content or recyclability figures in the sources reviewed.
  • Paper-specific share of deforestation-free sourcing is not reported; the 51% covers 12 materials combined, and the target year for that goal was not confirmed verbatim.
  • Scope 3 target level and year not captured from the section read.
  • Employee count as-of date not stated in the 20-F section read.
  • London Stock Exchange ticker taken from the RNS announcement header, not from the 20-F cover page.
  • Medicinal-product carve-outs under PPWR, UK Plastic Packaging Tax, Spanish plastic tax and US state EPR laws were not checked.
  • Ventolin and Augmentin turnover were not found in the results tables read.
  • Publication month of the Responsible Business 2025 report not stated in the text read, so its progress update is not listed as a dated development.
  • Kenya and South Africa are served via third-party distributors; the obligated producer was not checked.
  • No Ellen MacArthur, Plastics Pact or CGF membership found; absence is not proof of non-membership.
Evidence

Sources

  1. GSK plc – Annual Report on Form 20-F for fiscal year 2025Regulatory filing · published 6 Mar 2026 · consulted 13 Oct 2026
  2. GSK plc – Full year and fourth quarter 2025 results (RNS Final Results)Regulatory filing · published 4 Feb 2026 · consulted 13 Oct 2026
  3. GSK – Responsible Business 2025 (part of Annual Report 2025)Company publication · published 2026 · consulted 13 Oct 2026
  4. GSK – Materials and wasteCompany publication · consulted 13 Oct 2026
  5. GSK – Worldwide contactsCompany publication · consulted 13 Oct 2026
  6. GSK – Press release: positive pivotal phase III data for next generation low carbon version of Ventolin MDICompany publication · published 22 Oct 2025 · consulted 13 Oct 2026
  7. GSK – Media statement: regulatory submission in the EU for a lower carbon version of Ventolin MDICompany publication · published 4 Sep 2026 · consulted 13 Oct 2026

SPI analysis sections written by the SPI team on 14 October 2026. Not company-reported, not legal advice.

Targets in the register above link to their own source. Facts are summarised in the SPI team's words; quotes are marked.

Method

About the SPI Buyers Database

Purpose
To help packaging makers and suppliers see what large buyers have committed to publicly, by end use and region, and how far they have got.
Coverage
42 large brand owners and retailers so far, chosen for their size in packaging demand. It is not a complete list of buyers in any market.
Data sources
Each company's own sustainability, annual and ESG reports, press releases and filings, plus official sources where a pledge was made to a public body.
SPI Methodology
For each target we record the wording, the target year, the latest progress the company reports and a short quote from the source. Status says met or missed only when the company states the result; otherwise it shows in progress or not reported.
Limitations
Companies report on different bases and years. Headquarters countries and end uses are assigned by the SPI team and are not separately sourced. Rows have not yet been re-checked by a second SPI team member. No contacts, purchase volumes, supplier relationships or pack specifications are included.
Access
Free to read and to download as CSV. For an analysis of a buyer group for your products, ask for a buyer briefing.
ClosingAsk the SPI team

Ask the SPI team

Selling packaging to these companies?

We map a buyer's public commitments and deadlines to the materials and formats they affect, and assess the opportunity for converters and material suppliers.

Prefer email? Write to sales@strategicpackaginginsights.com.

Questions people bring
  1. Q1

    Which material should replace our current pack?

    We compare the realistic alternatives on recyclability evidence, regulatory fit and cost direction, and say where the evidence is thin.

  2. Q2

    How do our targets compare with our peers'?

    We benchmark the public packaging commitments and reported progress of the companies you name, each with its source.